ClinicalTrials.gg

Program

RGT001-075

A development code.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2, led by Regor Pharmaceuticals.

Furthest: phase 2, since Feb 24, 20223 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regor Pharmaceuticals30 open or runningphase 2since Feb 24, 2022Feb 24, 2022none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 24, 2022First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT05297045 · 17 enrolled · United States
  2. Feb 1, 2024Phase 2 study in ObesityNCT06277934 · 73 enrolled · United States
  3. Feb 14, 2025Phase 2 study in ObesityNCT06867718 · 267 enrolled · United States

TargetBeta

GLP1R →read by rule
“RGT001-075 is a small molecule GLP-1 agonist”study text, by rule · the study

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06867718Obesity · United States2CompletedNov 6, 2025267
NCT06277934Obesity · United States2CompletedAug 13, 202473
NCT05297045Diabetes Mellitus, Type 2 · United States2TerminatedMay 30, 202317

How it is read

Names in the registry

  • “RGT001-075”, 3 entries

Codes read as this program: RGT001075.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.